United States 119th Congress Status: In Committee Bipartisan · 42 D · 3 R cosponsors

HR 307 — ARC Act of 2025

Last action — Sponsor introductory remarks on measure. (CR H122)

  1. ✓
    Introduced
  2. 2
    In Committee
  3. 3
    Passed House
  4. 4
    Passed Senate
  5. 5
    To Executive
  6. 6
    Enacted

This bill is in committee in the House. Introduced January 09, 2025. It must pass committee before a floor vote.

Next likely step: a committee vote, then a floor vote in the House.

Odds of enactment

Low chance

Based on the sponsor, cosponsors, and committee posture, this bill has a low chance of becoming law.

Upgrade to see the exact probability and what's driving it.

A statistical estimate from our own model of past outcomes — an insight, not a guarantee. Policymaking is volatile.

Prognosis

Advancing 42% · moderate confidence

  • In Committee

    Current position in the legislative process.

  • 45 sponsors

    1 primary, 44 co-sponsors signed on.

  • Bipartisan support

    Sponsored across 2 parties (42 D · 3 R) — cross-party backing.

Based on stage, sponsorship breadth, committee status, recorded votes, and cross-state momentum — a description of the observable signals, not a prediction.

In plain language

HR 307 aims to address key provisions in energy and commerce legislation.

This bill has been introduced to handle important aspects related to energy and commerce. It has been referred to relevant committees for further consideration.

Summary

Amputation Reduction and Compassion Act of 2025 or the ARC Act of 2025 This bill provides for coverage of peripheral artery disease screening tests without cost-sharing under Medicare and Medicaid for certain at-risk individuals. It also requires the development of certain educational programs, a payment model, and Medicare quality measures to reduce amputations relating to such disease.

Bill Text

How this bill changes current law

6 changes Share ↗

Compared against current U.S. Code AI-generated reading aid — verify against the official bill.

The bill amends existing law to provide coverage for peripheral artery disease screening tests under Medicare and Medicaid without cost-sharing requirements for at-risk beneficiaries.

  • 42 U.S.C. 1395x

    peripheral artery disease screening tests furnished to at-risk beneficiaries (as such terms are defined in subsection (nnn)).

    This addition establishes coverage for peripheral artery disease screening tests for certain at-risk beneficiaries.

  • 42 U.S.C. 1395x

    The term 'peripheral artery disease screening test' means-- (A) noninvasive physiologic studies of extremity arteries (commonly referred to as ankle-brachial index testing); (B) arterial duplex scans of lower extremity arteries vascular; and (C) such other items and services as the Secretary determines, in consultation with relevant stakeholders, to be appropriate for screening for peripheral artery disease for at-risk beneficiaries.

    Defines peripheral artery disease screening tests to include specific non-invasive studies and allows for the inclusion of additional tests as determined by the Secretary.

  • 42 U.S.C. 1395x

    The term 'at-risk beneficiary' means an individual entitled to, or enrolled for, benefits under part A and enrolled for benefits under part B-- (A) who is 65 years of age or older; (B) who is at least 50 years of age but not older than 64 years of age with risk factors for atherosclerosis (such as diabetes mellitus, a history of smoking, hyperlipidemia, and hypertension) or a family history of peripheral artery disease; (C) who is younger than 50 years of age with diabetes mellitus and one additional risk factor for atherosclerosis; or (D) with a known atherosclerotic disease in another vascular bed such as coronary, carotid, subclavian, renal, or mesenteric artery stenosis, or abdominal aortic aneurysm.

    Establishes criteria for what constitutes an at-risk beneficiary for the purpose of peripheral artery disease screening.

  • 42 U.S.C. 1395l

    with respect to peripheral artery disease screening tests furnished to at-risk beneficiaries (as such terms are defined in section 1861(nnn)), the amount paid shall be 100 percent of the lesser of the actual charge for the services or the amount determined under the payment basis determined under section 1848;

    Ensures that Medicare pays 100% of the cost for peripheral artery disease screening tests for at-risk beneficiaries without any cost-sharing.

  • 42 U.S.C. 1395l

    such deductible shall not apply with respect to peripheral artery disease screening tests furnished to at-risk beneficiaries (as such terms are defined in section 1861(nnn))

    Exempts at-risk beneficiaries from deductibles for peripheral artery disease screening tests.

  • 42 U.S.C. 1395y

    in the case of peripheral artery disease screening tests furnished to at-risk beneficiaries (as such terms are defined in section 1861(nnn)), which are performed more frequently than is covered under such section;

    Establishes guidelines for Medicare coverage exclusions based on the frequency of peripheral artery disease screening tests provided.

Action History

  1. Introduced in House

  2. Introduced in House

  3. Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

  4. Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

  5. Sponsor introductory remarks on measure. (CR H122)

Sponsors

Sponsorship breakdown

Export CSV (upgrade) →

1 sponsors · 44 co-sponsors · 502 not signed on

Sponsors (1)

Co-sponsors (44)

Not signed on (502)

502 members have not signed on to this bill.

Show all 502 →

"Not signed on" means a member has not sponsored or co-sponsored this bill — it does not imply opposition. Members flagged Voted No have a recorded No vote on this bill.

Whip count is in markup. Polling the chamber and every recorded vote this session. Only the first open is slow. It’s instant for you after this. Calling the roll · Tallying · Engrossing

Subjects

healthcare education health-insurance
Cross-referencing the record. Reading this bill against every other bill in the corpus by meaning, not keywords. Only the first open is slow. It’s instant for you after this. Matching · Ranking · Engrossing

Frequently asked questions

What does HR 307 do?
Amputation Reduction and Compassion Act of 2025 or the ARC Act of 2025 This bill provides for coverage of peripheral artery disease screening tests without cost-sharing under Medicare and Medicaid for certain at-risk individuals. It also requires the development of certain educational programs, a payment model, and Medicare quality measures to reduce amputations relating to such disease.
Who sponsors HR 307?
HR 307 is sponsored by McIver, LaMonica (Democratic), Jackson, Jonathan L. (Democratic), Kelly, Robin L. (Democratic), Watson Coleman, Bonnie (Democratic), Sewell, Terri A. (Democratic), Davids, Sharice (Democratic), Johnson, Henry C. "Hank" (Democratic), McCollum, Betty (Democratic), Takano, Mark (Democratic), Brownley, Julia (Democratic), Meeks, Gregory W. (Democratic), Davis, Donald G. (Democratic), Sykes, Emilia Strong (Democratic), Thompson, Bennie G. (Democratic), Norton, Eleanor Holmes (Democratic), Castro, Joaquin (Democratic), Clarke, Yvette D. (Democratic), Lee, Summer L. (Democratic), Davis, Danny K. (Democratic), Trahan, Lori (Democratic), Beatty, Joyce (Democratic), Grijalva, Raúl M. (Democratic), Doggett, Lloyd (Democratic), Bergman, Jack (Republican), Stanton, Greg (Democratic), Cherfilus-McCormick, Sheila (Democratic), Carson, André (Democratic), Craig, Angie (Democratic), Wilson, Frederica S. (Democratic), Bishop, Sanford D. (Democratic), Kean, Thomas H. (Republican), Moylan, James C. (Republican), Mfume, Kweisi (Democratic), Wasserman Schultz, Debbie (Democratic), Johnson, Julie (Democratic), Waters, Maxine (Democratic), Frost, Maxwell (Democratic), Velázquez, Nydia M. (Democratic), Foushee, Valerie P. (Democratic), Gottheimer, Josh (Democratic), Thanedar, Shri (Democratic), Veasey, Marc A. (Democratic), Plaskett, Stacey E. (Democratic), Ross, Deborah K. (Democratic), and Soto, Darren (Democratic).
What is the current status of HR 307?
This bill is in committee in the House. Introduced January 09, 2025. It must pass committee before a floor vote.
Where can I track HR 307?
Track HR 307 free on One Click Politics — get push/email alerts when it moves.

Make your voice heard on HR 307

Find the representatives who decide this bill and tell them where you stand — for yourself, or mobilize your whole list in one click with One Click Politics advocacy software.

Find my representatives → Run a campaign

Stay ahead of HR 307

Last checked for changes 3 months ago · updated continuously

One Click Politics tracks every bill in Congress and all 50 states.

Track this bill →